Genomic Biomarker Market, by Indication (Oncology, Cardiovascular diseases, Neurological diseases, and Others), by End User (Hospitals, Diagnostic & Research Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Mid

Genomic Biomarker Market, by Indication (Oncology, Cardiovascular diseases, Neurological diseases, and Others), by End User (Hospitals, Diagnostic & Research Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Genomic biomarkers are either DNA or RNA characteristics that are associated with a physiological process, immunological process or therapeutic response. A genomic biomarker reveals the expression, function, and regulation of a gene. DNA characteristics that act as genomic biomarkers include DNA modification, insertions, deletions, cytogenetic rearrangements, single nucleotide polymorphisms (SNPs), and others. Genomic biomarkers based on RNA characteristics comprise of RNA sequence, microRNA levels, RNA processing, etc. Genomic biomarkers are of high clinical significance as these can be used for diagnostic purposes. Genomic biomarkers aid in monitoring the progress of a disease such as cancer and also guide the targeted drug deliveries. Rapid research and development has helped researchers to understand the benefits of genomic biomarkers as a non-invasive clinical diagnostic tool. Genomic biomarkers have been widely used to detect single gene mutations predisposing to disease such as familial hypercholesterolemia disorder.

Genomic biomarkers play a major role in drug development process by identifying differences in drug metabolism and drug toxicity between different individuals. This property of genetic biomarkers can be used to design personalized medicines that will ensure administration of proper dosage of medicine based on the requirement of a particular patient rather than a generalized population. Genomic biomarkers are also used in several preclinical and clinical toxicity studies to have a better understanding of adverse drug reactions, which then helps in making better decisions with regards to drug development and clinical management of patients.

Market Dynamics

Increasing adoption of genomic biomarkers-based clinical trials in drug development, oncology, cardiology, and neurology could contribute to the growth of the market over the forecast period. According to an article published by Future Science in June 2021, biomarkers such as genomic biomarkers play a crucial role in development of novel drugs and are therefore a part of early-phase clinical trials. Moreover, in 2019, Sunnybrook Health Sciences Centre initiated a clinical trial study to identify new genomic biomarkers that would reveal response to neoadjuvant chemotherapy in breast cancer patients.

Market players are focusing on launch of products and approvals, which is expected to strengthen their position in the global market. For instance, in 2021, Personal Genome Diagnostics Inc., an American cancer genome analysis company, received U.S. Food and Drug Administration (FDA) clearance for its product PGDx elio tissue complete, which is a genomic biomarker-based cancer diagnostic kit. This kit involves an extensive analysis of all the genes and their interactions with each other. Rising approvals for such products drive the market growth of genomic biomarkers.

Market players are involved in expanding their product portfolio by entering into licensing agreements with other companies or research organizations. For instance, in 2018, Personal Genome Diagnostics Inc. signed an agreement with Memorial Sloan Kettering Cancer Center, a New York based cancer treatment and research center, for development and commercialization of products under tumor mutation burden (TMB) genomic biomarker status. TMB is a genomic biomarker, which can be measured to determine body’s response to cancer immunotherapy. This is expected to drive the growth of the genomic biomarker market.

Key features of the study:
This report provides an in-depth analysis of global genomic biomarker market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global genomic biomarker market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Liquid Genomics, Inc., AROS Applied Biotechnology A/S, Myriad Genetics, Inc., QIAGEN, Eurofins Scientific, Genomic Health, Bio-Rad Laboratories, Inc., Epigenomics AG, and Aepodia
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global genomic biomarker market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the genomic biomarker market
Detailed Segmentation:
Global Genomic Biomarker Market, By Indication:
Oncology
Cardiovascular diseases
Neurological diseases
Others
Global Genomic Biomarker Market, By End User:
Hospitals
Diagnostic & Research Laboratories
Others
Global Genomic Biomarker Market, By Region:
North America
By Indication:
Oncology
Cardiovascular diseases
Neurological diseases
Others
By End User:
Hospitals
Diagnostic & Research Laboratories
Others
By Country:
U.S.
Canada
Latin America
By Indication:
Oncology
Cardiovascular diseases
Neurological diseases
Others
By End User:
Hospitals
Diagnostic & Research Laboratories
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Indication:
Oncology
Cardiovascular diseases
Neurological diseases
Others
By End User:
Hospitals
Diagnostic & Research Laboratories
Others
Diagnostic & By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Indication:
Oncology
Cardiovascular diseases
Neurological diseases
Others
By End User:
Hospitals
Diagnostic & Research Laboratories
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East
By Indication:
Oncology
Cardiovascular diseases
Neurological diseases
Others
By End User:
Hospitals
Diagnostic & Research Laboratories
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Indication:
Oncology
Cardiovascular diseases
Neurological diseases
Others
By End User:
Hospitals
Diagnostic & Research Laboratories
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Thermo Fisher Scientific*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
F. Hoffmann-La Roche AG
Liquid Genomics, Inc.
AROS Applied Biotechnology A/S
Myriad Genetics, Inc.
QIAGEN
Eurofins Scientific
Genomic Health
Bio-Rad Laboratories, Inc.
Epigenomics AG
Aepodia
“*” marked represents similar segmentation in other categories in the respective section.